Truist Financial upgraded BioMarin Pharmaceutical to strong-buy, and Morgan Stanley lowered its target price on the company's stock.

The entities involved

• BioMarin Pharmaceutical →

  American company

  Nothing else this week.

• Truist Financial →

  American bank holding company, formerly known as BB&T Corporation

  • Corning saw rating changes and price target adjustments from Morgan Stanley and Truist Financial, alongside increased shareholding by the Czech National Bank.Sun 11:07
  • Retailers like Kroger and Walmart intensify competition in the grocery market, while Erste Group and Truist Financial report market movements.Sat 18:11
• Morgan Stanley →

  U.S. investment bank

  • Bank of America and Morgan Stanley are restricting third-party AI agents amid cybersecurity scares and a declared bank run threat.Sun 13:24
  • Morgan Stanley set a price target on Rockwell Automation shares on October 25, 2026.Sun 10:27

Related events

• Truist Financial lifted its price target and Jefferies Financial Group reissued a buy rating for Pediatrix Medical Group.Jun 30
• Multiple financial institutions, including Morgan Stanley, Citigroup, and TD Cowen, boosted price targets and upgraded ratings on October 16, 2026.Oct 16
• Truist Financial raised its target price on Teva Pharmaceutical Industries Ltd. stock.Aug 16
• Raymond James Financial reaffirmed a strong-buy rating and Morgan Stanley set a $25.00 price objective for VIR Biotechnology.Oct 10
• Truist Financial cut its price target and lowered its rating, while TD Cowen raised its target price, with MarketBeat aggregating consensus ratings.Jun 30